Global Acute Lung Injury Market

Acute Lung Injury Comprehensive Study by Therapy (Pharmacotherapy, Mechanical Ventilation, Adjunctive Procedures, Fluid Management, Others), End-users (Hospitals, Clinics, Ambulatory Surgical Centres, Others), Symptoms (Low Blood Pressure, Severe Shortness of Breath, Confusion, Extreme Tiredness) Players and Region - Global Market Outlook to 2028

Acute Lung Injury Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Acute Lung Injury
Acute lung injury (ALI) is a form of acute respiratory failure, defined by hypoxemia and the presence of bilateral infiltrates on chest radiograph, and often referred to by its most severe subset known as acute respiratory distress syndrome (ARDS). Acute lung injury is a common condition that is associated with high mortality. It is characterized by acute severe hypoxia that is not due to left atrial hypertension. It is diagnosed clinically and radiological based on the presence of non-cardiopulmonary edema and respiratory failure in a critically ill patient. The symptoms associated with acute lung injury include low blood pressure, severe shortness of breath, confusion and extreme tiredness. The factors such as the Increasing Number of Patients Affected with Lung Injury and Growing Awareness about Heath Diagnostics are driving the global acute lung injury market.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Acute Lung Injury market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

GlaxoSmithKline plc. (United Kingdom), INO Therapeutics, LLC (United States), Octapharma AG (Switzerland), Ono Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (United States), Chiesi SpA (Italy), B. Braun Melsungen AG (Germany), Altor BioScience Corporation (United States), FirstString Research, Inc. (United States) and CompleGen, Inc. (United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Medtronic plc (Ireland), ResMed (United States), Philips Healthcare (Netherlands) and Drägerwerk AG & Co. KGaA (Germany).

Segmentation Overview
AMA Research has segmented the market of Global Acute Lung Injury market by and Region.



On the basis of geography, the market of Acute Lung Injury has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Therapy, the sub-segment i.e. Pharmacotherapy will boost the Acute Lung Injury market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-users, the sub-segment i.e. Hospitals will boost the Acute Lung Injury market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Low Blood Pressure will boost the Acute Lung Injury market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Development of New Treatment Strategies and Increased Research and Development Activities

Market Growth Drivers:
Increasing Number of Patients Affected With Lung Injury, Growing Awareness about Heath Diagnostics and Increasing Number of Diagnostic Centres and Hospitals

Challenges:
Lack of Specific Treatment and Stringent Government Rules and Regulations

Restraints:
High Cost of the Treatment for Acute Lung Injury and Lack of Skilled Professionals

Opportunities:
Rising Geriatric Population Worldwide, Technological Advancements in the Healthcare Industry and Growth in the Healthcare Industry

Market Leaders and their expansionary development strategies
In October 2023, Pulm Logic partners with Lung Foundation Australia this collaboration focuses on raising awareness about ALI/ARDS and supporting research efforts for developing new treatment strategies, including the use of ECLA devices.
In September 2023, Pulm Logic ALung System has launched this extracorporeal lung assist device (ECLA) offers advanced lung support for patients with severe ALI/ARDS, potentially bridging the gap to lung recovery or transplantation.


Key Target Audience
Acute Lung Injury Treatment Providers, Research Professionals, Research Institutes, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Therapy
  • Pharmacotherapy
  • Mechanical Ventilation
  • Adjunctive Procedures
  • Fluid Management
  • Others

By End-users
  • Hospitals
  • Clinics
  • Ambulatory Surgical Centres
  • Others

By Symptoms
  • Low Blood Pressure
  • Severe Shortness of Breath
  • Confusion
  • Extreme Tiredness

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Number of Patients Affected With Lung Injury
      • 3.2.2. Growing Awareness about Heath Diagnostics
      • 3.2.3. Increasing Number of Diagnostic Centres and Hospitals
    • 3.3. Market Challenges
      • 3.3.1. Lack of Specific Treatment
      • 3.3.2. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Development of New Treatment Strategies
      • 3.4.2. Increased Research and Development Activities
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Acute Lung Injury, by Therapy, End-users, Symptoms and Region (value and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Acute Lung Injury (Value)
      • 5.2.1. Global Acute Lung Injury by: Therapy (Value)
        • 5.2.1.1. Pharmacotherapy
        • 5.2.1.2. Mechanical Ventilation
        • 5.2.1.3. Adjunctive Procedures
        • 5.2.1.4. Fluid Management
        • 5.2.1.5. Others
      • 5.2.2. Global Acute Lung Injury by: End-users (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Ambulatory Surgical Centres
        • 5.2.2.4. Others
      • 5.2.3. Global Acute Lung Injury by: Symptoms (Value)
        • 5.2.3.1. Low Blood Pressure
        • 5.2.3.2. Severe Shortness of Breath
        • 5.2.3.3. Confusion
        • 5.2.3.4. Extreme Tiredness
      • 5.2.4. Global Acute Lung Injury Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Acute Lung Injury (Price)
  • 6. Acute Lung Injury: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. INO Therapeutics, LLC (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Octapharma AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Ono Pharmaceutical Co., Ltd. (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Eli Lilly and Company (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Chiesi SpA (Italy)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. B. Braun Melsungen AG (Germany)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Altor BioScience Corporation (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. FirstString Research, Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. CompleGen, Inc. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Acute Lung Injury Sale, by Therapy, End-users, Symptoms and Region (value and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Acute Lung Injury (Value)
      • 7.2.1. Global Acute Lung Injury by: Therapy (Value)
        • 7.2.1.1. Pharmacotherapy
        • 7.2.1.2. Mechanical Ventilation
        • 7.2.1.3. Adjunctive Procedures
        • 7.2.1.4. Fluid Management
        • 7.2.1.5. Others
      • 7.2.2. Global Acute Lung Injury by: End-users (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Ambulatory Surgical Centres
        • 7.2.2.4. Others
      • 7.2.3. Global Acute Lung Injury by: Symptoms (Value)
        • 7.2.3.1. Low Blood Pressure
        • 7.2.3.2. Severe Shortness of Breath
        • 7.2.3.3. Confusion
        • 7.2.3.4. Extreme Tiredness
      • 7.2.4. Global Acute Lung Injury Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Acute Lung Injury (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Acute Lung Injury: by Therapy(USD Million)
  • Table 2. Acute Lung Injury Pharmacotherapy , by Region USD Million (2017-2022)
  • Table 3. Acute Lung Injury Mechanical Ventilation , by Region USD Million (2017-2022)
  • Table 4. Acute Lung Injury Adjunctive Procedures , by Region USD Million (2017-2022)
  • Table 5. Acute Lung Injury Fluid Management , by Region USD Million (2017-2022)
  • Table 6. Acute Lung Injury Others , by Region USD Million (2017-2022)
  • Table 7. Acute Lung Injury: by End-users(USD Million)
  • Table 8. Acute Lung Injury Hospitals , by Region USD Million (2017-2022)
  • Table 9. Acute Lung Injury Clinics , by Region USD Million (2017-2022)
  • Table 10. Acute Lung Injury Ambulatory Surgical Centres , by Region USD Million (2017-2022)
  • Table 11. Acute Lung Injury Others , by Region USD Million (2017-2022)
  • Table 12. Acute Lung Injury: by Symptoms(USD Million)
  • Table 13. Acute Lung Injury Low Blood Pressure , by Region USD Million (2017-2022)
  • Table 14. Acute Lung Injury Severe Shortness of Breath , by Region USD Million (2017-2022)
  • Table 15. Acute Lung Injury Confusion , by Region USD Million (2017-2022)
  • Table 16. Acute Lung Injury Extreme Tiredness , by Region USD Million (2017-2022)
  • Table 17. South America Acute Lung Injury, by Country USD Million (2017-2022)
  • Table 18. South America Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 19. South America Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 20. South America Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 21. Brazil Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 22. Brazil Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 23. Brazil Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 24. Argentina Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 25. Argentina Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 26. Argentina Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 27. Rest of South America Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 28. Rest of South America Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 29. Rest of South America Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 30. Asia Pacific Acute Lung Injury, by Country USD Million (2017-2022)
  • Table 31. Asia Pacific Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 32. Asia Pacific Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 33. Asia Pacific Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 34. China Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 35. China Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 36. China Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 37. Japan Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 38. Japan Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 39. Japan Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 40. India Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 41. India Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 42. India Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 43. South Korea Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 44. South Korea Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 45. South Korea Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 46. Taiwan Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 47. Taiwan Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 48. Taiwan Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 49. Australia Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 50. Australia Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 51. Australia Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 52. Rest of Asia-Pacific Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 53. Rest of Asia-Pacific Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 54. Rest of Asia-Pacific Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 55. Europe Acute Lung Injury, by Country USD Million (2017-2022)
  • Table 56. Europe Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 57. Europe Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 58. Europe Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 59. Germany Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 60. Germany Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 61. Germany Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 62. France Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 63. France Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 64. France Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 65. Italy Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 66. Italy Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 67. Italy Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 68. United Kingdom Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 69. United Kingdom Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 70. United Kingdom Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 71. Netherlands Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 72. Netherlands Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 73. Netherlands Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 74. Rest of Europe Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 75. Rest of Europe Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 76. Rest of Europe Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 77. MEA Acute Lung Injury, by Country USD Million (2017-2022)
  • Table 78. MEA Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 79. MEA Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 80. MEA Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 81. Middle East Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 82. Middle East Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 83. Middle East Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 84. Africa Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 85. Africa Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 86. Africa Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 87. North America Acute Lung Injury, by Country USD Million (2017-2022)
  • Table 88. North America Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 89. North America Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 90. North America Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 91. United States Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 92. United States Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 93. United States Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 94. Canada Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 95. Canada Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 96. Canada Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 97. Mexico Acute Lung Injury, by Therapy USD Million (2017-2022)
  • Table 98. Mexico Acute Lung Injury, by End-users USD Million (2017-2022)
  • Table 99. Mexico Acute Lung Injury, by Symptoms USD Million (2017-2022)
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Acute Lung Injury: by Therapy(USD Million)
  • Table 111. Acute Lung Injury Pharmacotherapy , by Region USD Million (2023-2028)
  • Table 112. Acute Lung Injury Mechanical Ventilation , by Region USD Million (2023-2028)
  • Table 113. Acute Lung Injury Adjunctive Procedures , by Region USD Million (2023-2028)
  • Table 114. Acute Lung Injury Fluid Management , by Region USD Million (2023-2028)
  • Table 115. Acute Lung Injury Others , by Region USD Million (2023-2028)
  • Table 116. Acute Lung Injury: by End-users(USD Million)
  • Table 117. Acute Lung Injury Hospitals , by Region USD Million (2023-2028)
  • Table 118. Acute Lung Injury Clinics , by Region USD Million (2023-2028)
  • Table 119. Acute Lung Injury Ambulatory Surgical Centres , by Region USD Million (2023-2028)
  • Table 120. Acute Lung Injury Others , by Region USD Million (2023-2028)
  • Table 121. Acute Lung Injury: by Symptoms(USD Million)
  • Table 122. Acute Lung Injury Low Blood Pressure , by Region USD Million (2023-2028)
  • Table 123. Acute Lung Injury Severe Shortness of Breath , by Region USD Million (2023-2028)
  • Table 124. Acute Lung Injury Confusion , by Region USD Million (2023-2028)
  • Table 125. Acute Lung Injury Extreme Tiredness , by Region USD Million (2023-2028)
  • Table 126. South America Acute Lung Injury, by Country USD Million (2023-2028)
  • Table 127. South America Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 128. South America Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 129. South America Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 130. Brazil Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 131. Brazil Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 132. Brazil Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 133. Argentina Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 134. Argentina Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 135. Argentina Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 136. Rest of South America Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 137. Rest of South America Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 138. Rest of South America Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 139. Asia Pacific Acute Lung Injury, by Country USD Million (2023-2028)
  • Table 140. Asia Pacific Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 141. Asia Pacific Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 142. Asia Pacific Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 143. China Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 144. China Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 145. China Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 146. Japan Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 147. Japan Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 148. Japan Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 149. India Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 150. India Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 151. India Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 152. South Korea Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 153. South Korea Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 154. South Korea Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 155. Taiwan Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 156. Taiwan Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 157. Taiwan Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 158. Australia Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 159. Australia Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 160. Australia Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 161. Rest of Asia-Pacific Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 162. Rest of Asia-Pacific Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 163. Rest of Asia-Pacific Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 164. Europe Acute Lung Injury, by Country USD Million (2023-2028)
  • Table 165. Europe Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 166. Europe Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 167. Europe Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 168. Germany Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 169. Germany Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 170. Germany Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 171. France Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 172. France Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 173. France Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 174. Italy Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 175. Italy Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 176. Italy Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 177. United Kingdom Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 178. United Kingdom Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 179. United Kingdom Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 180. Netherlands Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 181. Netherlands Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 182. Netherlands Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 183. Rest of Europe Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 184. Rest of Europe Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 185. Rest of Europe Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 186. MEA Acute Lung Injury, by Country USD Million (2023-2028)
  • Table 187. MEA Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 188. MEA Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 189. MEA Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 190. Middle East Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 191. Middle East Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 192. Middle East Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 193. Africa Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 194. Africa Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 195. Africa Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 196. North America Acute Lung Injury, by Country USD Million (2023-2028)
  • Table 197. North America Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 198. North America Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 199. North America Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 200. United States Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 201. United States Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 202. United States Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 203. Canada Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 204. Canada Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 205. Canada Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 206. Mexico Acute Lung Injury, by Therapy USD Million (2023-2028)
  • Table 207. Mexico Acute Lung Injury, by End-users USD Million (2023-2028)
  • Table 208. Mexico Acute Lung Injury, by Symptoms USD Million (2023-2028)
  • Table 209. Research Programs/Design for This Report
  • Table 210. Key Data Information from Secondary Sources
  • Table 211. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Acute Lung Injury: by Therapy USD Million (2017-2022)
  • Figure 5. Global Acute Lung Injury: by End-users USD Million (2017-2022)
  • Figure 6. Global Acute Lung Injury: by Symptoms USD Million (2017-2022)
  • Figure 7. South America Acute Lung Injury Share (%), by Country
  • Figure 8. Asia Pacific Acute Lung Injury Share (%), by Country
  • Figure 9. Europe Acute Lung Injury Share (%), by Country
  • Figure 10. MEA Acute Lung Injury Share (%), by Country
  • Figure 11. North America Acute Lung Injury Share (%), by Country
  • Figure 12. Global Acute Lung Injury share by Players 2022 (%)
  • Figure 13. Global Acute Lung Injury share by Players (Top 3) 2022(%)
  • Figure 14. Global Acute Lung Injury share by Players (Top 5) 2022(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 17. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2022
  • Figure 18. INO Therapeutics, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 19. INO Therapeutics, LLC (United States) Revenue: by Geography 2022
  • Figure 20. Octapharma AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 21. Octapharma AG (Switzerland) Revenue: by Geography 2022
  • Figure 22. Ono Pharmaceutical Co., Ltd. (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Ono Pharmaceutical Co., Ltd. (Japan) Revenue: by Geography 2022
  • Figure 24. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 25. Eli Lilly and Company (United States) Revenue: by Geography 2022
  • Figure 26. Chiesi SpA (Italy) Revenue, Net Income and Gross profit
  • Figure 27. Chiesi SpA (Italy) Revenue: by Geography 2022
  • Figure 28. B. Braun Melsungen AG (Germany) Revenue, Net Income and Gross profit
  • Figure 29. B. Braun Melsungen AG (Germany) Revenue: by Geography 2022
  • Figure 30. Altor BioScience Corporation (United States) Revenue, Net Income and Gross profit
  • Figure 31. Altor BioScience Corporation (United States) Revenue: by Geography 2022
  • Figure 32. FirstString Research, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 33. FirstString Research, Inc. (United States) Revenue: by Geography 2022
  • Figure 34. CompleGen, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 35. CompleGen, Inc. (United States) Revenue: by Geography 2022
  • Figure 36. Global Acute Lung Injury: by Therapy USD Million (2023-2028)
  • Figure 37. Global Acute Lung Injury: by End-users USD Million (2023-2028)
  • Figure 38. Global Acute Lung Injury: by Symptoms USD Million (2023-2028)
  • Figure 39. South America Acute Lung Injury Share (%), by Country
  • Figure 40. Asia Pacific Acute Lung Injury Share (%), by Country
  • Figure 41. Europe Acute Lung Injury Share (%), by Country
  • Figure 42. MEA Acute Lung Injury Share (%), by Country
  • Figure 43. North America Acute Lung Injury Share (%), by Country
List of companies from research coverage that are profiled in the study
  • GlaxoSmithKline plc. (United Kingdom)
  • INO Therapeutics, LLC (United States)
  • Octapharma AG (Switzerland)
  • Ono Pharmaceutical Co., Ltd. (Japan)
  • Eli Lilly and Company (United States)
  • Chiesi SpA (Italy)
  • B. Braun Melsungen AG (Germany)
  • Altor BioScience Corporation (United States)
  • FirstString Research, Inc. (United States)
  • CompleGen, Inc. (United States)
Additional players considered in the study are as follows:
Medtronic plc (Ireland) , ResMed (United States) , Philips Healthcare (Netherlands) , Drägerwerk AG & Co. KGaA (Germany)
Select User Access Type

Key Highlights of Report


Dec 2023 206 Pages 72 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Acute Lung Injury Market Quantitative research analysis
Global Acute Lung Injury Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as GlaxoSmithKline plc. (United Kingdom), INO Therapeutics, LLC (United States), Octapharma AG (Switzerland), Ono Pharmaceutical Co., Ltd. (Japan), Eli Lilly and Company (United States), Chiesi SpA (Italy), B. Braun Melsungen AG (Germany), Altor BioScience Corporation (United States), FirstString Research, Inc. (United States) and CompleGen, Inc. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Development of New Treatment Strategies " is seen as one of major influencing trends for Acute Lung Injury Market during projected period 2022-2028.
The Acute Lung Injury market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Acute Lung Injury Market Report?

Have a Query? Click Here

Other Related Reports

Telmisartan and Hydrochlorothiazide Drug Comprehensive Study by Type (80 mg/12.5 mg tablets, 40 mg/12.5 mg tablets, 80 mg/25 mg tablets), Application (Hypertension, Fluid Retention, Prevents Heart At...
$ 3750
Actinic Keratosis Therapeutics Comprehensive Study by Type (Combination Therapy, Photodynamic Therapy), Application (Hospitals & Oncology Centers, Dermatology Clinics, Ambulatory Surgical Centers), D...
$ 3650
Opthalmology Drugs Comprehensive Study by Type (Prescription Drugs, Over-the-Counter Drugs), Application (Maintenance and Servicing, User Acceptance and Adaptation), Indication (Dry Eye, Glaucoma, In...
$ 3750
Embolotherapy Comprehensive Study by Type (Embolic Agents, Microspheres, Embolic Coils (Detachable Coils, Pushable Coils), Liquid Embolic Agents, Embolic Plug Systems, Detachable Balloons, Support De...
$ 4800
Plaque Psoriasis Treatment Comprehensive Study by Type (Topical Therapy, Phototherapy, Systemic Agents, Biologic Therapies), Application (Hospitals, Clinics, Others), Drug Class (TNF-α Inhibitor...
$ 3350
Cerebral Infarction Therapy Comprehensive Study by Type (Partial Anterior Circulation Infarct (PACI), Total Anterior Circulation Infarct (TACI), Posterior Circulation Infarct (POCI)), Application (Ho...
$ 3650